barchart.com
Cure8 news brief
Why This Matters
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
Knowing which drugs and companies are active helps patients and clinicians track emerging therapies and potential trial opportunities.
Who Should Pay Attention
Adult patients with Crohn’s disease, clinicians treating IBD, researchers following drug development, and patients interested in clinical trials or future treatment options.
Study Snapshot
Story typeBusiness news
Evidence typeMarket or Business News
Source depthFull source text
What To Know
This article is a market/report summary rather than original clinical data. It highlights active development across many drug classes (biologics, small molecules, S1P modulators, etc.) and names individual drugs and study actions such as phase 3 initiations and combination studies. It does not provide patient-level results or new efficacy/safety findings.
If you follow IBD treatment development, this is useful to see which companies and drug candidates are active and which trials have recently started or been announced. It can help you spot drugs you may hear about in future trial recruitment or approval news.
For details on specific drugs, trial designs, eligibility, or results, consult the primary trial registries, company press releases, or your clinical team.
Keep In Mind
This article is a press-release-style market summary based on DelveInsight’s paid report and company announcements; it lists drugs and trial starts but does not report trial results or regulatory decisions. For clinical implications, rely on peer-reviewed studies, trial registries, and regulatory agency communications.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationbarchart.com
Indexed viaGoogle News
Source typeBusiness news
PublishedJun 16, 2026, 6:38 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Crohn's Disease Market Across The 7MM To Witness Upsurge In Growth From USD 9 Billion In 2023
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
Crohn's Disease Clinical Trials And Studies 2025: EMA, PDMA, FDA Approvals, Mechanism ...
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...